مباشر

BioPharma DiveCreate Medicines raises $122M to bolster in vivo CAR-T therapies FierceBiotechBioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS Endpoints NewsDrugmakers have to go through rigorous tests to get a lower tariff rate FierceBiotechBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?Promega BlogCharged Molecular Glues: The Molecular Trojan Horse That Slipped Past Biology’s Toughest Bouncer Clinical OMICsContact Lenses Show Promise for Depression BioPharma DiveBiogen pushing tau drug forward despite Alzheimer’s study failure Endpoints NewsDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data Endpoints NewsAstraZeneca follows Merck with Phase 3 win in bladder cancer Endpoints NewsMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack FierceBiotechCreate Medicines fashions $122M fundraise for in vivo CAR-T dreams BioPharma DiveWith new data, Regenxbio to seek FDA approval of Duchenne gene therapy

BioWorld ١٤ مايو ٢٠٢٦

Pfizer discloses new dual calcitonin/amylin receptor agonists

Pfizer Inc. has synthesized substituted fused heteroaryl lactam compounds acting as dual calcitonin (CALCR; CT-R)/amylin receptor agonists potentially useful fo...

Pfizer Inc. has synthesized substituted fused heteroaryl lactam compounds acting as dual calcitonin (CALCR; CT-R)/amylin receptor agonists potentially useful for the treatment of obesity and type 2 diabetes.